Paper Review Records
All Paper Review Records
5 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
143
days
PIK3CA Mutations in Advanced or Recurrent Endometrial Cancer: An Exploratory Molecular Profiling From the Phase II MITO END-3 Study
Authors
Anna Passarelli; Giovanni Luca Scaglione; Daniela Califano; Michele Bartoletti; Domenica Lorusso; Sabrina Chiara Cecere; Anna Fagotti; Alberto Farolfi; Claudia Andreetta; Jole Ventriglia; Laura Arenare; Carmela Pisano; Daniela Russo; Maria Teresa Perri; Saverio Cinieri; Simona Scalone; Ugo De Giorgi; Valentina Arcangeli; Elena Zafarana; Maria Chiara Cannizzaro; Serafina Mammoliti; Tommaso Ambrosio; Rossella De Cecio; Clorinda Schettino; Francesco Perrone; Sandro PignataShow moreShow less
Affiliations
1. Uro-Gynecological Medical Oncology, Istituto Nazionale Tumori—IRCCS—Fondazione G. Pascale, Naples, Italy; 2. Bioinformatics Unit, Istituto Dermopatico dell'Immacolata IDI-IRCCS, Rome, Italy; 3. Microenvironment Molecular Targets Unit, Istituto Nazionale Tumori—IRCCS—Fondazione G. Pascale, Naples, Italy; 4. Unit of Medical Oncology and Cancer Prevention, Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy; 5. Division of Gynecologic Oncology, Humanitas San Pio X, Milan, Italy; 6. Department of Biomedical Sciences, Humanitas University, Milan, Italy; 7. Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy; 8. Medical Oncology, Breast & GYN Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy; 9. Department of Medical Oncology, “S. Maria della Misericordia” University Hospital, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy; 10. Clinical Trial Unit, Istituto Nazionale Tumori—IRCCS—Fondazione G. Pascale, Naples, Italy; 11. U.O.C. Oncologia Medica-Ospedale Senatore Antonio Perrino, Brindisi, Italy; 12. Department of Experimental Medicine, University of Salento, Fazzi Hospital, Lecce, Italy; 13. Romagna Cancer Registry IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” (IRST), Meldola, Italy; 14. Department of Oncology, Hospital of Prato Azienda USL Toscana Centro, Prato, Italy; 15. AOM Liguria, Azienda Ospedaliera Metropolitana di Genova, Genoa, Italy; 16. Division of Anatomic Pathology and Cytopathology, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Naples, ItalyShow moreShow less
184
days
Tailoring Escalated Adjuvant Chemotherapy for Multifocal and Multicentric Breast Cancer With Low Tumor Burden
Authors
Yonghui Su; Jiaqi Ying; Zhuozhao Zhan; Tingting Wu; Yena Yu; Wanxin Gao; Yizi ZhengShow moreShow less
Affiliations
1. Department of Breast Surgery, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China; 2. Department of Breast Surgery, Zhejiang Key Laboratory of Intelligent Cancer Biomarker Discovery and Translation, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China; 3. Department of Mathematics and Computer Science, Eindhoven University of Technology, Eindhoven, the NetherlandsShow moreShow less
84
days
Decoding Treatment Response and Prognosis in Unresectable Locally Advanced Non–Small Cell Lung Cancer by Integrating Spatiotemporal Heterogeneity From 18F-FDG Positron Emission Tomography-Computed Tomography: A Multicenter Study
Authors
Yu Ji; Jiaqi Wang; Meixia Zhou; Yaru Wang; Zhengjun Dai; Jingsong ZhengShow moreShow less
Affiliations
1. Department of Radiology, The Second Qilu Hospital of Shandong University, Jinan, Shandong, China; 2. Department of Cancer Medical Center, People's Hospital of Chengwu County, Heze, Shandong, China; 3. Department of Radiology, Shandong University, Jinan, Shandong, China; 4. Institute of Research and Clinical Innovations, Neusoft Medical Systems Co. Ltd, Beijing, China; 5. Center for Nuclear Medicine and Molecular Imaging, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, ChinaShow moreShow less
133
days
Tumor-Free Circulating Tumor DNA in Node-Negative Rectal Cancers Undergoing Neoadjuvant Chemotherapy, Excision, and Observation in the Phase II NEO Trial (CO.28)
Authors
Jonathan M. Loree; Emma Titmuss; Carl J. Brown; Thereasa Rich; Kimberly Banks; Vallerie Gordon; Sunil Patel; Marianne Krahn; Antonio Caycedo-Marulanda; Manoj Raval; Dongsheng Tu; Derek J. Jonker; Christopher J. O'Callaghan; Hagen F. KenneckeShow moreShow less
Affiliations
1. BC Cancer, Vancouver, BC, Canada; 2. Canadian Cancer Trials Group, Kingston, ON, Canada; 3. St Paul's Hospital, Vancouver, BC, Canada; 4. Guardant Health, Palo Alto, CA; 5. Saskatchewan Cancer Agency, Saskatoon, SK, Canada; 6. Kingston Health Sciences Centre, Kingston, ON, Canada; 7. Cancer Care Manitoba, Winnipeg, MB, Canada; 8. Northern Ontario School of Medicine, Sudbury, ON, Canada; 9. The Ottawa Hospital, Ottawa, ON, Canada; 10. Oregon Health Sciences Institute, Portland, ORShow moreShow less
87
days
Efficacy Study of Vemurafenib in Children With Recurrent or Progressive BRAFV600E- or BRAFInsT-Mutant Brain Tumors: PNOC002
Authors
Theodore Nicolaides; Raoull Hoogendijk; Marie Jaeger-Krause; Girish Dhall; Stewart Goldman; Amar Gajjar; Lindsay Kilburn; Sarah Leary; Jane Minturn; Nicholas Whipple; Divya Ramakrishnan; Janel Long-Boyle; Mariam Aboian; Michael Prados; Annette M. Molinaro; Sabine MuellerShow moreShow less
Affiliations
1. Caris Life Sciences, Irving, TX; 2. Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; 3. Department of Neurology, Brain Tumor Center, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands; 4. Department of Pediatrics, University of California, San Francisco, San Francisco, CA; 5. Division of Hematology & Oncology, University of Alabama, Birmingham, AL; 6. Phoenix Children's Hospital, University of Arizona College of Medicine, Phoenix, AZ; 7. St Jude Children's Research Hospital, Memphis, TN; 8. Center for Cancer and Blood Disorders, Brain Tumor Institute, Children's National Health System, Washington, DC; 9. Seattle Children's Hospital, Seattle, WA; 10. Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; 11. University of Utah, Salt Lake City, UT; 12. Department of Radiology, Stanford University School of Medicine, Stanford, CA; 13. Department of Clinical Pharmacy, University of California San Francisco (UCSF) School of Pharmacy, San Francisco, CA; 14. Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA; 15. Department of Neurology, University of California, San Francisco, San Francisco, CA; 16. University Children's Hospital Zurich, Zurich, SwitzerlandShow moreShow less
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review62 days
Median65 days